This is a non-invasive prenatal test (NIPT) that analyzes cell-free DNA in a pregnant individual’s blood to screen for specific chromosomal abnormalities in the developing fetus. The test evaluates the risk of conditions such as Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), and Patau syndrome (Trisomy 13), as well as sex chromosome aneuploidies. The analysis focuses on identifying whether there is an atypical number of chromosomes present in the fetal DNA.
This type of screening offers several benefits, including high accuracy and the ability to be performed relatively early in pregnancy, typically starting around 10 weeks of gestation. It provides expectant parents with valuable information to make informed decisions about their pregnancy and potential further diagnostic testing. Historically, prenatal screening involved methods with higher false-positive rates, leading to unnecessary anxiety and invasive procedures. This test has significantly reduced the need for such invasive follow-up procedures.